HK1167335A1 - Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof - Google Patents

Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof

Info

Publication number
HK1167335A1
HK1167335A1 HK12108089.1A HK12108089A HK1167335A1 HK 1167335 A1 HK1167335 A1 HK 1167335A1 HK 12108089 A HK12108089 A HK 12108089A HK 1167335 A1 HK1167335 A1 HK 1167335A1
Authority
HK
Hong Kong
Prior art keywords
sorafenib
production method
sodium alginate
agent containing
containing sodium
Prior art date
Application number
HK12108089.1A
Other languages
English (en)
Chinese (zh)
Inventor
李新建
洪宏
魯格
Original Assignee
北京聖醫耀科技發展有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京聖醫耀科技發展有限責任公司 filed Critical 北京聖醫耀科技發展有限責任公司
Publication of HK1167335A1 publication Critical patent/HK1167335A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK12108089.1A 2009-04-16 2012-08-17 Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof HK1167335A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009100824496A CN101536986B (zh) 2009-04-16 2009-04-16 含索拉非尼的海藻酸钠靶向缓释微球血管栓塞剂及其制备和应用
PCT/CN2010/071749 WO2010118683A1 (zh) 2009-04-16 2010-04-14 含索拉非尼的海藻酸钠靶向缓释微球血管拴塞剂及其制备和应用

Publications (1)

Publication Number Publication Date
HK1167335A1 true HK1167335A1 (en) 2012-11-30

Family

ID=41120529

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12108089.1A HK1167335A1 (en) 2009-04-16 2012-08-17 Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof

Country Status (9)

Country Link
US (1) US20120093932A1 (de)
EP (1) EP2420227B1 (de)
JP (1) JP5802193B2 (de)
KR (1) KR20120022942A (de)
CN (1) CN101536986B (de)
CA (1) CA2758820C (de)
DK (1) DK2420227T3 (de)
HK (1) HK1167335A1 (de)
WO (1) WO2010118683A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10653684B2 (en) * 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
CN102258477B (zh) * 2010-05-28 2014-09-03 北京宏医耀科技发展有限公司 一种抗移植免疫排斥反应的新型j2-海藻酸钠微球缓释免疫抑制剂、制备方法和用途
JP6205373B2 (ja) * 2012-02-03 2017-09-27 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｎｄｇａ誘導体およびソラフェニブを含む組成物、ならびにがんの処置におけるこれらの使用
KR101255647B1 (ko) * 2012-06-26 2013-04-16 주식회사 두산에코비즈넷 복원성이 우수한 알지네이트 건조 비드의 제조방법
US10647004B2 (en) * 2016-07-07 2020-05-12 The Board Of Trustees Of The Leland Stanford Junior University Air-bladder enhanced with gecko-adhesive for grasping applications
WO2018218208A1 (en) 2017-05-26 2018-11-29 Bruin Biosciences, Inc. Chemoembolization agents
CN111773428A (zh) * 2020-08-05 2020-10-16 华中科技大学 一种药物缓释海藻酸类栓塞微球及其制备方法
CN112237586A (zh) * 2020-10-14 2021-01-19 暨南大学 重楼皂苷与索拉菲尼在制备抗肿瘤联用药物中的应用
CN113197866A (zh) * 2021-04-23 2021-08-03 复旦大学附属华山医院 一种射线不可透的介入治疗用载药栓塞微球及其制备方法
CN115112560B (zh) * 2022-08-29 2022-11-29 杭州瑞睫医疗科技有限公司 一种栓塞剂体外模拟装置及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0470569B1 (de) * 1990-08-08 1995-11-22 Takeda Chemical Industries, Ltd. Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
WO2005062810A2 (en) * 2003-12-18 2005-07-14 Mediscovery, Llc Treatment of primary and metastatic neoplastic diseases with tetraarsenic decaoxide
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
EP1870089A4 (de) * 2005-04-15 2012-10-03 Beijing Shengyiyao Science & Technology Dev Co Ltd Gynäkologisches arzneimittelhaltiges mikrokugelförmiges vaskuläres suppositorium aus natriumalginat und sein herstellungsverfahren
US20070031338A1 (en) * 2005-08-02 2007-02-08 Zabinski Peter P Embolized cryoablation for treatment of tumors
EP1954272A2 (de) * 2005-10-31 2008-08-13 Bayer Pharmaceuticals Corporation Krebsbehandlung mit sorafenib
CA2753844A1 (en) * 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
CN101336890A (zh) * 2008-05-30 2009-01-07 济南基福医药科技有限公司 一种抗癌缓释凝胶注射剂
CN101301470A (zh) * 2008-07-11 2008-11-12 济南基福医药科技有限公司 含新生血管抑制剂及硼替佐米的抗癌组合物

Also Published As

Publication number Publication date
CN101536986A (zh) 2009-09-23
US20120093932A1 (en) 2012-04-19
JP2012524031A (ja) 2012-10-11
CN101536986B (zh) 2011-05-04
EP2420227A1 (de) 2012-02-22
EP2420227A4 (de) 2012-12-19
DK2420227T3 (en) 2014-03-24
JP5802193B2 (ja) 2015-10-28
WO2010118683A1 (zh) 2010-10-21
CA2758820A1 (en) 2010-10-21
KR20120022942A (ko) 2012-03-12
EP2420227B1 (de) 2014-01-22
CA2758820C (en) 2014-09-30

Similar Documents

Publication Publication Date Title
HK1167335A1 (en) Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof
EP2177294A4 (de) Verfahren zur herstellung einer metallmikropartikel und kolloidale metalllösung mit der metallmikropartikel
EP2429496A4 (de) Zusammensetzung und verfahren zur herstellung künstlicher und biologisch abbaubarer hautstützstrukturen auf polysaccharidgelbasis
EP2460539A4 (de) Arzneimittelträger in form von nano- oder mikrokugeln, verfahren zu seiner herstellung sowie zusammensetzung daraus und verwendung davon
EP2441814A4 (de) Wärmedehnbare mikrokugeln, verfahren zu ihrer herstellung und verwendung davon
EP2735343A4 (de) Feuerlöschmittel und feuerlöschverfahren damit
PL2659035T3 (pl) Włókna hialuronowe, sposób ich wytwarzania i zastosowanie
ZA200711043B (en) Method of preparing microfibrillar polysaccharide
EP2346981A4 (de) Kieselgurprodukte, herstellungsverfahren dafür und ihre verwendung
EP2521553A4 (de) Verfahren und zusammensetzungen für gezielte wirkstoffentwicklung
EP2573070A4 (de) Kristallform von (s)-4-hydroxy-2-oxo-1-pyrrolidinacetamid, herstellungsverfahren und verwendung davon
EP2428268A4 (de) Katalysator, verfahren zu seiner herstellung und seine verwendung
EP2577451A4 (de) Verfahren, vorrichtungen und herstellungsartikel zur bereitstellung von softwareanwendungen
PL2554050T3 (pl) Środek zawierający związany chlor oraz sposób jego wytwarzania i sposób jego zastosowania
EP2537867A4 (de) Modifizierte hyaluronsäure und/oder salz davon, herstellungsverfahren dafür und kosmetikartikel damit
ZA201503651B (en) Mineral suspending agent, method of making, and use thereof
ZA201402501B (en) Palladium separating agent ,method for producing same and use of same
IL221946A (en) A method for increasing the solubility of an anti-retirement substance
EP2576576A4 (de) Biphosphonsäure auf heterocyclyl-pyridinyl-basis, pharmazeutisch zulässiges salz davon, zusammensetzung daraus und verwendungsverfahren dafür
PL2281822T3 (pl) Nowe pochodne dihydroindolonów, sposób ich wytwarzania i zawierające je kompozycje farmaceutyczne
EP2766375A4 (de) Herstellung von neuen fluorverbindungen, herstellungsverfahren und daraus hergestellte zusammensetzungen
WO2012142328A3 (en) Polymer microsphere compositions for localized delivery of therapeutic agents
EP2014682A4 (de) Verfahren zur herstellung von pektin, geliermittel und gelatinöses lebensmittel unter verwendung davon
HK1171190A1 (en) Heteroaryl benzamides, compositions and methods of use
HK1158632A1 (en) Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same 2--1--2-

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190417